Quick Answer
TENAX THERAPEUTICS, INC. reported Research And Development Expense of $32.67 million for the year ending 2025.
- TENAX THERAPEUTICS, INC. showed an increase of +157.1% in Research And Development Expense from 2024 to 2025.
- This data is from TENAX THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), TENAX THERAPEUTICS, INC.'s Research And Development Expense has grown by 1,118.3%.
- Historical annual values: Fiscal year 2025: $32.67 million | Fiscal year 2024: $12.71 million | Fiscal year 2023: $3.23 million | Fiscal year 2022: $5.38 million | Fiscal year 2021: $25.15 million | Fiscal year 2020: $4.56 million | Fiscal year 2019: $3.47 million | Fiscal year 2018: $1.24 million | Fiscal year 2017: $3.53 million | Fiscal year 2016: $13.14 million | Fiscal year 2015: $6.66 million | Fiscal year 2014: $3.00 million | Fiscal year 2013: $2.46 million | Fiscal year 2012: $2.46 million | Fiscal year 2011: $2.68 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: